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Reviewers' Comments:  
 
Reviewer #1:  
Remarks to the Author:  
Proto et al. provide evidence that a specific mutation in the Plasmodium falciparum (malaria parasite) 
invasion ligand EBA165 that renders the protein into a pseudogene and is present in all isolates 
sequenced to date is critical for parasite invasion into human red blood cells. A functional copy of 
EBA165 was found by the authors in the reference genomes and field isolate DNA for all closely 
related ape malaria parasites (Laverania), suggesting the antigen is required for ape-RBC invasion. 
One key difference in RBC receptors between human and ape cells is the presence of both Neu5Gc and 
Neu5Ac sialic acid residues on ape cells and of only Neu5Ac residues on human RBCs due to disruption 
of the human N-glycolylneuraminic acid gene (CMAH) that converts Neu5Ac to Neu5Gc.  
The authors show that recombinant ape malaria EBA165 (PrEBA165) and full-length corrected (frame 
shift repaired) P. falciparum EBA165 (PfEBA165) bound to chimpanzee RBCs and also to cultured 
transgenic human RBCs that expressed the ape Neu5Gc. Binding assays showed that both PrEBA165 
and PfEBA165 bind to Neu5Gc sialic acid residues of ape RBCs, but not to Neu5Ac residues. These 
experiments convincingly show a strong link between EBA165 and binding to ape Neu5Gc labelled 
proteins sialoglycoproteins.  
The authors then go onto repair the frameshift mutations in the P. falciparum 3D7 parasite line to 
create a functional EBA165. However, no change in growth or invasion phenotypes was observed with 
this transfected line. Further investigation revealed that the expression of repaired EBA165 was highly 
downregulated. This suggests that expression of functional EBA165 is deleterious to parasite growth, 
and the incorporation of the Frameshift mutation into this invasion ligand may have been a key step in 
P. falciparum’s adaption to human RBCs.  
This novel finding is significant since it potentially identifies a key step in the transition of P. 
falciparum’s ape infecting ancestors into the major human pathogen it has become. The manuscript is 
well written and should be of interest to readers. The conclusions are based on strong evidence that 
has been achieved using nicely designed experiments.  
 
Major comments  
 
-This paper demonstrates EBA165 binding to Neu5Gc sialic acid residues (neuraminidase sensitive) 
using recombinant protein in human/chimpanzee RBC binding, cultured human RBCs expressing 
Neu5Gc residues and with a glycan array featuring both Neu5Gc and Neu5Ac residues. This is very 
strong binding assay data, but if the study lacks anything, it is the ability to confirm EBA165s use of 
Neu5Gc during merozoite invasion in growth assays, and whether expression of PfEBA165 is 
deleterious to parasite invasion directly. There are clear difficulties in testing this such as 3D7 
parasites with a frameshift corrected EBA165 completely downregulating expression of this now 
functional antigen. The Duraisingh group previously showed that parasite growth could be maintained 
in cRBCs (Bei et al 2010). Did the authors attempt to select for genetically modified 3D7 parasites 
expressing functional EBA165 by growing them in cRBCs expressing CHAM and Neu5Gc on the cRBC 
surface? If successful, these could then be used to directly investigate EBA165 during invasion into 
both Neu5Gc +ve and -ve cells. If this was not attempted, could the authors comment on whether it is 
feasible using the current scale of cRBC cultures? Could this be done to really nail down the properties 
of PfEBA165 during invasion.  
-In figure S4, the authors suggest that sialic acid treatment of Hs and Pt cells did not cause a change 
in invasion for the EBA165 frameshift corrected transfected 3D7 lines. I suggest that there may be a 
trend towards increased neuraminidase sensitivity (where there any statistical tests done to test for 
this?), particularly for S4 C, suggesting a movement towards a sialic acid dependent invasion 
pathway. Despite EBA165 expression dropping, this might make sense given the loss of RH4 
expression. RH4 is an important non-sialic acid dependent pathway for 3D7 invasion. Loss of RH4 
could switch the parasite more towards a neuraminidase sensitive, sialic acid dependent, invasion 
pathway. Can the authors confirm that the variation evident for the neuraminidase treatments has 
been tested directly and discuss the implications of loss of Rh4 expression on invasion pathways for 
the genetically engineered parasites.  
-In figure S4, Panels A and B are in the wrong order compared to the Figure legend.  
-There isn’t a lot of statistical analysis of the data evident in the text, and for several graphs there is 
an opportunity to strengthen the comparative analysis by doing so. It is also not clear for some data 
sets whether the experiment was repeated to assess reproducibility or whether a single experiment 
with triplicate wells was done. Error bars are also not defined in all figures. This should be rectified.  
-The experiments are well done and would be readily repeatable if other researchers had access to 
some of the rarer host cell types such as the Chimpanzee and cRBCs.  
 
Minor comments  
There is no line numbering to highlight some minor text changes. So below I past in the sentence and 
highlight the text that needs modifying in capitals.  
- Both were unable to bind to control cRBCs (pLVX, Fig 3B), just as they had been unable to bind to 
mature human erythrocytes taken from circulation, but they could bind cRBCs differentiated from 
CMAH expressing HSCs, which differed only in the sialic acid variant that was expressed on the red 
blood CELL surface.  
- This and other molecular studies are starting to reveal the exact steps that were required for P. 
falciparum to emerge as one of the most significant PATHOGENS in human history.  
- To quantify invasion into target ERYTHROCYTES, cultures were washed in PBS and stained with SYBR 
Green I (Invitrogen) DNA dye, at 1:5000 final concentration.  
-Recombinant PfEBA165, PrEBA165 and PfEBA175 ECTODOMAINS were expressed as  




Reviewer #2:  
Remarks to the Author:  
REVIEW of “Adaptation of Plasmodium falciparum to humans involved the loss of an ape-specific 
erythrocyte invasion ligand. “ by Proto et al for Nature Communications.  
 
SUMMARY  
EBA165 belongs to a family of several Plasmodium parasite erythrocyte binding ligands of the 
Laveranian group that infect humans and other apes. The EBA ligands play a role in helping the 
merozoite parasite stage to attach to and invade RBCs. Here Proto et al establish that all in human P. 
falciparum species tested the EBA165 gene does not produce a protein due to a 5’ frame shift 
mutation. In Pf-like Laveranian parasites that infect African apes EBA165 does produce a functional 
protein that is shown to bind to certain types of Neu5Gc sugars present on ape RBCs but not on 
human RBCs whose proteins are decorated with Neu5Ac sugars. Recombinant PfEBA165 produced 
from the frame shift repaired gene is still functional and able to bind ape RBCs but not human RBCs. 
To show that ape sugars are important for RBC binding, stem cell derived human RBCs were 
transfected with the chimpanzee CMAH gene that converts Neu5Ac to Neu5Gc. PfEBA165 bound to the 
modified human RBCs along with an ape EBA165. When the frame shifted PfEBA165 was repaired by 
CRISPR to produce a functional protein the modified Pf parasites were able to grow in human RBCs but 
only if expression of functional PfEBA165 was greatly reduced. This indicated that expression of 
PfEBA165 is incompatible with growth in human RBCs and the inactivation of EBA165 must have been 
an important event when Pf’s ancestors moved from apes into humans.  
 
MAJOR COMMENTS  
This is an excellent and fascinating paper and I can find no major criticisms of the work. It would be 
interesting to know the why the expression of functional PfEBA165 in Pf parasites is incompatible with 
growth in human RBCs. It was speculated that functional PfEBA165 might prevent other invasion 
pathways such as that employing PfEBA175 from working properly as shown in Fig 6. There is no 
evidence to support the EBA175 hypothesis but I don’t think this is needed at this stage. Also, it would 
be interesting to know which Neu5Gc decorated ape protein(s) is the EBA165 receptor and if this is 
the same as that in CMAH-expressing human RBCs but that can be done in the future.  
 
MINOR COMMENTS  
1. In Fig S3 the legend states that “cRBCs expressed lower levels of DARC and CD71 than mature 
erythrocytes, as has been previously shown.” Shown where? Unless I am missing something the 
graphs show CD71 is higher in cRBCs than human RBCs.  
2. In the methods it states the oligo sequences are shown in Table S1 but Table S1 shows gene 
expression data. Table S1 is labeled as Table 1 in the table but S1 in the legend.  





-This paper demonstrates EBA165 binding to Neu5Gc sialic acid residues (neuraminidase 
sensitive) using recombinant protein in human/chimpanzee RBC binding, cultured human RBCs 
expressing Neu5Gc residues and with a glycan array featuring both Neu5Gc and Neu5Ac 
residues. This is very strong binding assay data, but if the study lacks anything, it is the ability to 
confirm EBA165s use of Neu5Gc during merozoite invasion in growth assays, and whether 
expression of PfEBA165 is deleterious to parasite invasion directly. There are clear difficulties in 
testing this such as 3D7 parasites with a frameshift corrected EBA165 completely 
downregulating expression of this now functional antigen. The Duraisingh group previously 
showed that parasite growth could be maintained in cRBCs (Bei et al 2010). Did the authors 
attempt to select for genetically modified 3D7 parasites expressing functional EBA165 by 
growing them in cRBCs expressing CHAM and Neu5Gc on the cRBC surface? If successful, 
these could then be used to directly investigate EBA165 during invasion into both Neu5Gc +ve 
and -ve cells. If this was not attempted, could the authors comment on whether it is feasible 
using the current scale of cRBC cultures? Could this be done to really nail down the properties 
of PfEBA165 during invasion. 
 
We thank the reviewer for their question, which we agree is important and had previously 
considered a great deal before submission of the manuscript. Unfortunately we believe that the 
experiment is simply technically impossible, at least at this time.There are three hurdles - the 
inefficiencies of transfection in P. falciparum, the length of time that such selection experiments 
usually take, and the low volumes of cRBCs that are generated in vitro. Transfection efficiencies 
in P. falciparum are such that we believe that only a handful of parasites are successfully 
transfected in each experiment, based on the 5-8 weeks it can take for parasites to reappear in 
culture after transfection. Selection for different invasion pathways have only ever been carried 
out successfully in one strain to our knowledge (and the submitting authors on this manuscript 
have tried several other strains without success), and in this case it also takes several weeks for 
parasites to appear. These two factors together require a long period of continuous culture, 
almost certainly on the scale of months. Generating each batch of cRBCS takes considerable 
resources  both in time (c. 3 weeks for each batch) and materials, and produces 10ul of CMAH 
cRBCs (1x108 cells) at best before filtration to remove the very young nucleated cells. At ~20% 
recovery post-filtration, this leaves 2x107 cells. This number of cells is sufficient for short-term 
invasion and growth assays, such as those carried out in this manuscript and others previously 
published but is inadequate to support even small-scale continuous parasite culture. Producing 
a consistent supply of CMAH cRBCs to supplement a culture over a period of months is 
therefore unfortunately just not possible at this time. We completely agree that the idea is an 
important one however, and we have now added text to the Discussion explaining the concept 




-In figure S4, the authors suggest that sialic acid treatment of Hs and Pt cells did not cause a 
change in invasion for the EBA165 frameshift corrected transfected 3D7 lines. I suggest that 
there may be a trend towards increased neuraminidase sensitivity (where there any statistical 
tests done to test for this?), particularly for S4 C, suggesting a movement towards a sialic acid 
dependent invasion pathway. Despite EBA165 expression dropping, this might make sense 
given the loss of RH4 expression. RH4 is an important non-sialic acid dependent pathway for 
3D7 invasion. Loss of RH4 could switch the parasite more towards a neuraminidase sensitive, 
sialic acid dependent, invasion pathway. Can the authors confirm that the variation evident for 
the neuraminidase treatments has been tested directly and discuss the implications of loss of 
Rh4 expression on invasion pathways for the genetically engineered parasites. 
  
We thank the reviewer for contributing this new insight. As predicted by the reviewer, the 
increased sensitivity of the double edited strains to neuraminidase treatment during invasion is 
statistically significant, and is consistent with the RNAseq data which shows down-regulation of 
PfRH4. We have modified the figures and text to reflect this and have provided additional 
consideration on implications on the loss of RH4 in the Discussion.     
 
 
-In figure S4, Panels A and B are in the wrong order compared to the Figure legend. 
 
This error has now been corrected. 
  
 
-There isn’t a lot of statistical analysis of the data evident in the text, and for several graphs 
there is an opportunity to strengthen the comparative analysis by doing so. It is also not clear for 
some data sets whether the experiment was repeated to assess reproducibility or whether a 
single experiment with triplicate wells was done. Error bars are also not defined in all figures. 
This should be rectified. 
 
We have made several changes to help clarify how replicates were conducted and make clear 
where statistical tests have been applied. Figure legends have been modified to clarify the 
experimental repeats performed and to define all error bars. In addition, the outcomes of 
statistical test have also been added to the appropriate data (see Figs. 4C, Supplementary Figs 
4B and 4C). 
 
 
-The experiments are well done and would be readily repeatable if other researchers had 
access to some of the rarer host cell types such as the Chimpanzee and cRBCs. 
 
We’re pleased that experiments have been designed and presented in a way that will help other 
researchers in the field. Obtaining chimpanzee RBCs for even these small number of 
experiments was very challenging, for good reason, and we are grateful to the support of our 




There is no line numbering to highlight some minor text changes. So below I past in the 
sentence and highlight the text that needs modifying in capitals. 
 
- Both were unable to bind to control cRBCs (pLVX, Fig 3B), just as they had been unable to 
bind to mature human erythrocytes taken from circulation, but they could bind cRBCs 
differentiated from CMAH expressing HSCs, which differed only in the sialic acid variant that 
was expressed on the red blood CELL surface. 
 
- This and other molecular studies are starting to reveal the exact steps that were required for P. 
falciparum to emerge as one of the most significant PATHOGENS in human history. 
 
- To quantify invasion into target ERYTHROCYTES, cultures were washed in PBS and stained 
with SYBR Green I (Invitrogen) DNA dye, at 1:5000 final concentration. 
 
-Recombinant PfEBA165, PrEBA165 and PfEBA175 ECTODOMAINS were expressed as 
secreted mono-biotinylated proteins in HEK239E cells. 
 











This is an excellent and fascinating paper and I can find no major criticisms of the work. It would 
be interesting to know the why the expression of functional PfEBA165 in Pf parasites is 
incompatible with growth in human RBCs. It was speculated that functional PfEBA165 might 
prevent other invasion pathways such as that employing PfEBA175 from working properly as 
shown in Fig 6. There is no evidence to support the EBA175 hypothesis but I don’t think this is 
needed at this stage. Also, it would be interesting to know which Neu5Gc decorated ape 
protein(s) is the EBA165 receptor and if this is the same as that in CMAH-expressing human 
RBCs but that can be done in the future. 
 
We are pleased the reviewer found the paper and model presented of interest. The experiment 
suggested would certainly have value, however, identifying host targets of parasite invasion 
ligands remains a considerable challenge in the field, even with the addition of new screening 
tools such as AVEXIS. In addition in this case, the limited supply of chimp erythrocytes and 
cRBC make biochemical approaches next to impossible. Despite these challenges, we 
absolutely agree that identifying the chimpanzee receptor for EBA165 is a topic of some 




1. In Fig S3 the legend states that “cRBCs expressed lower levels of DARC and CD71 than 
mature erythrocytes, as has been previously shown.” Shown where? Unless I am missing 
something the graphs show CD71 is higher in cRBCs than human RBCs.  
 
We thank the reviewer for their observation, which is absolutely right. We have corrected the 
figure legend to make it clear that there is significantly higher expression of CD71, but lower 
expression of DARC on cRBCs compared to mature erythrocytes. This is consistent with what 
was have reported previously (see Dankwa et al. 2016, Nature Communications, and 
Giarratana et al. 2011. Blood, for CD71 expression) for cRBCs, and probably relates to the 
slightly younger age of such cells. This point has also now been made in the manuscript 
 
2. In the methods it states the oligo sequences are shown in Table S1 but Table S1 shows gene 
expression data. Table S1 is labeled as Table 1 in the table but S1 in the legend.  
 
The oligo table has now been added to the Supplementary Information file as Supplementary 
Table 2, and the text has been modified to correct the error. The incorrect Table 1 label from 
Supplementary Table 1 has also been removed.    
  
Reviewers' Comments:  
 
Reviewer #1:  
Remarks to the Author:  
A second review of the manuscript reveals it is in good shape, except for Supplementary Fig 4 B and 
C. Inclusion of the number of experimental replicates reveals that each data set was only done once. 
This is understandable for Pt (Chimpanzee) blood experiments. But the data for Human RBCs is 
therefore weakened. Quite simply, probably shouldn't do statistics on a single experiment. If 
additional experiments are not to be done, I suggest talking about this in terms of trends. I also 
suggest modifying the figures using the following.  
-Create a seperate figure for Hs +/- neuraminidase and use the data available in Figure 4C to create a 
figure establishing the trend across two biological replicates. This would be stronger than having two 
seperate trends and is clearer then comparing between Supplementary 4B and 4C to see repeat Hs 
experiments with Neuraminidase.  
-Follow that with the Pt +/- neuraminidase figure only.  
-Finish with the Hs +/- remaining enzyme treatments (I don't think having data for YB4 adds anything 
here).  
Any additional data available that could increase the number of biological replicates would be of 
benefit. 
Given the limited importance of these observations in the overall manuscript, I feel that modification 
of the figures, inclusion of any available repeat data and discussing the data in terms of trends (rather 
than as statistically significant) would be sufficient. If the authors want to strengthen this data with 
repeat experiments for Hs RBCs, thats up to them.  
REVIEWERS' COMMENTS: 
 
Reviewer #1 (Remarks to the Author):  
 
A second review of the manuscript reveals it is in good shape, except for Supplementary Fig 
4 B and C. Inclusion of the number of experimental replicates reveals that each data set was 
only done once. This is understandable for Pt (Chimpanzee) blood experiments. But the 
data for Human RBCs is therefore weakened. Quite simply, probably shouldn't do statistics 
on a single experiment. If additional experiments are not to be done, I suggest talking about 
this in terms of trends. I also suggest modifying the figures using the following. 
-Create a seperate figure for Hs +/- neuraminidase and use the data available in Figure 4C 
to create a figure establishing the trend across two biological replicates. This would be 
stronger than having two seperate trends and is clearer then comparing between 
Supplementary 4B and 4C to see repeat Hs experiments with Neuraminidase. 
-Follow that with the Pt +/- neuraminidase figure only. 
-Finish with the Hs +/- remaining enzyme treatments (I don't think having data for YB4 adds 
anything here).  
Any additional data available that could increase the number of biological replicates would 
be of benefit. 
Given the limited importance of these observations in the overall manuscript, I feel that 
modification of the figures, inclusion of any available repeat data and discussing the data in 
terms of trends (rather than as statistically significant) would be sufficient. If the authors want 
to strengthen this data with repeat experiments for Hs RBCs, thats up to them. 
 
We thank the reviewer for their detailed and helpful reading of the revised manuscript, and 
we have adjusted Supplementary Figure 4 exactly as requested. 
 
